Orthofix Medical Inc. Form 4 Filings

Orthofix Medical Inc. (OFIX) reported purchases of its common stock by Juniper Targeted Opportunity Fund, L.P.: 120,000 shares on September 18, 2026, at a weighted average of $8.7393 per share, and 190,000 shares on September 21, 2026, at a weighted average of $8.8599 per share. The reported price ranges were $8.65–$8.81 and $8.63–$8.98, respectively. Juniper Investment Company, LLC, John A. Bartholdson, and Alexis P. Michas were identified as 10% owners. Juniper Investment Company was identified as the fund’s investment manager, and Bartholdson and Michas as managing members who shared voting and dispositive power. All three disclaimed beneficial ownership except to the extent of their pecuniary interests. No Rule 10b5-1 plan is reported.

Orthofix Medical Inc. (symbol: OFIX) is the issuer of record for a Form 4 filing submitted to the SEC.

Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, its President, Global Limb Recon, sold 150 shares of common stock on September 1, 2026 at $9.39 per share in an open-market transaction under a Rule 10b5-1 trading plan. After this sale, he directly holds 51,069 shares, which include 36,028 previously reported restricted stock units.

Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, President, Global Limb Recon, sold 1,295 shares of common stock on 2026-08-18 at $10.09 per share. The sale was executed solely to satisfy tax withholding obligations under a pre-approved, mandatory sell-to-cover arrangement and involved no discretion by Fisher. Following this transaction, he holds 51,219 shares directly, including 36,028 restricted stock units and 1,881 shares acquired under Orthofix's Stock Purchase Plan.

Orthofix Medical Inc. (symbol: OFIX) is the issuer of record for a Form 4 filing submitted to the SEC.

Orthofix Medical Inc. executive Aviva McPherron reported selling 3,670 shares of common stock at $9.38 per share on an open market transaction. According to the footnote, the sale was mandated to satisfy tax withholding for restricted stock unit settlement under a pre-approved sell-to-cover program. McPherron still holds 66,330 shares directly, including 44,748 restricted stock units and 2,147 shares acquired through Orthofix’s Stock Purchase Plan.

Orthofix Medical Inc. director Alan Lee Bazaar received an equity award of 14,965 deferred stock units of common stock. The units were granted at no cash cost and will vest in full on the first anniversary of the grant date, conditioned on continued board service.

After this grant, Bazaar holds 65,489 shares and units in total, including 42,929 previously reported deferred stock units and 700 shares acquired under Orthofix’s Stock Purchase Plan. Each deferred stock unit represents the right to receive one share of common stock, which will settle within 45 days after his service with Orthofix ends.

Orthofix Medical Inc. director Charles R. Kummeth reported receiving an award of 14,965 deferred stock units of common stock as a compensation grant. The units were granted at $0.00 per share, indicating they are not an open-market purchase but an equity award.

The deferred stock units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit represents the right to receive one share of Orthofix common stock, which will be delivered within 45 days after his termination of service. Following this award, Kummeth holds 76,305 shares in total, including 42,343 previously reported deferred stock units and 2,103 shares acquired under Orthofix’s Stock Purchase Plan.

Orthofix Medical Inc. director Jason Hannon reported receiving an award of 14,965 deferred stock units of common stock on June 10, 2026. These units vest in full on the first anniversary of the grant date, as long as he continues serving the company.

Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock, which will be delivered within 45 days after his service with the company ends. Following this grant, Hannon directly holds 87,662 deferred stock units and shares, including 63,631 previously reported deferred stock units and 2,103 shares acquired through Orthofix's Stock Purchase Plan.

Orthofix Medical Inc. director Michael Finegan reported receiving an award of 20,721 deferred stock units of common stock. These units vest in full on the first anniversary of the grant date, contingent on his continued service. Each deferred stock unit represents the right to receive one Orthofix common share, which will be delivered within 45 days after his service with the company ends. Following this award and previously reported positions, Finegan now holds a total of 81,617 Orthofix shares and deferred stock units, including 55,805 earlier deferred units and 3,505 shares acquired under Orthofix's Stock Purchase Plan.

Orthofix Medical Inc. director Vickie L. Capps received a grant of 14,965 deferred stock units of common stock on the grant date. The award vests in full on the first anniversary of the grant, contingent on continued board service, and each unit represents the right to one share.

After this grant, Capps directly holds 43,300 shares and deferred stock units in total, including 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan. Vested deferred stock units will convert into common stock within 45 days after her service with Orthofix ends.

HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.

Orthofix Medical Inc. director John B. Henneman III received an equity award of 14,965 deferred stock units on common stock. The units were granted at no cash cost and vest in full on the first anniversary of the grant date, contingent on continued board service.

Each deferred stock unit represents a right to receive one share of Orthofix common stock, which will be delivered within 45 days after his service with the company ends. Following this award, Henneman holds 105,774 shares and units directly, including 48,347 deferred stock units that were previously reported.

BURRIS WAYNE reported acquisition or exercise transactions in this Form 4 filing.

Orthofix Medical Inc. director Wayne Burris received a grant of 14,965 deferred stock units of common stock at no cost. These units vest in full on the first anniversary of the grant date, contingent on his continued service with the company through that date.

Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock, settling within 45 days after his service with the company ends. Including 44,156 previously reported deferred stock units, his direct holdings now total 65,504 shares represented by deferred stock units.

Maniar Shweta reported acquisition or exercise transactions in this Form 4 filing.

Orthofix Medical Inc. director Shweta Maniar received an award of 14,965 deferred stock units of common stock at no purchase price as equity compensation. The units vest in full on the first anniversary of the grant date, conditioned on continued service. Each unit represents a contingent right to receive one share of common stock, which will be delivered within 45 days after her service with the company ends. Following this grant, she holds a total of 69,038 deferred stock units, including 48,347 units that were previously reported.

Orthofix Medical Inc. director Michael E. Paolucci received an equity compensation grant of 14,965 deferred stock units of common stock at no cost. These units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit will convert into one share of common stock within 45 days after his service with the company ends. Following this award, he directly holds 102,727 units and shares, including 73,541 previously reported deferred stock units and 814 shares acquired under Orthofix's Stock Purchase Plan.

Orthofix Medical Inc. reported an insider transaction involving funds managed by Juniper Investment Company, LLC. A Form 4 shows that Juniper Targeted Opportunity Fund, L.P., for which Juniper Investment Company acts as investment manager, completed an open-market sale of 242,000 shares of Orthofix common stock at a weighted average price of $10.6992 per share, with individual trade prices ranging from $10.2450 to $10.9500. After this sale, Juniper Targeted Opportunity Fund, L.P. held 3,461,216 shares indirectly. Related funds advised by Juniper Investment Company also held 45,426 shares through Juniper Multi-Strategy Fund, L.P. and 935,901 shares through Juniper Targeted Opportunities, L.P. Juniper Investment Company, and managing members John A. Bartholdson and Alexis P. Michas, state they may be deemed to beneficially own these holdings but disclaim beneficial ownership beyond their pecuniary interest.

Orthofix Medical Inc. director John B. Henneman III made an open-market purchase of 5,000 shares of common stock at $12.259 per share. Following this transaction, he holds 90,809 shares directly, which the footnote explains includes 48,347 deferred stock units and 2,103 shares acquired under Orthofix's Stock Purchase Plan.

Orthofix Medical Inc. shareholder entities associated with Engine Capital reported open-market purchases of the company’s common stock. Engine Capital, L.P. and Engine Lift Capital, LP together bought 184,896 shares between May 5 and May 7, 2026 at prices around $11.99–$12.23 per share. These shares are held indirectly through the Engine investment funds, and the reporting persons expressly limit beneficial ownership to their respective pecuniary interests. One filing line also updates that Engine Jet Capital, L.P. holds 344,652 shares of Orthofix common stock.

Orthofix Medical Inc. CLO Jorge Andres Cedron reported an open-market sale of 3,743 shares of common stock at $12.82 per share on April 16, 2026. According to the footnote, these shares were sold solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, Compensation and Talent Development Committee–mandated sell-to-cover requirement, leaving the executive with 59,006 shares, including 44,353 previously reported restricted stock units. The sale was made without any exercise of discretion by the reporting person.

Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, reported an open-market sale of 4,269 shares of common stock at $11.92 per share. According to the disclosure, the sale was executed solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-approved sell-to-cover arrangement.

The transaction was carried out without any exercise of discretion by Vitale. Following this tax-related sale, he holds 160,449 shares of Orthofix common stock, which includes 127,256 previously reported restricted stock units.

Orthofix Medical Inc. director Vickie L. Capps bought a total of 5,000 shares of common stock in open-market transactions. The purchases occurred on March 9–10, 2026 at prices around $12.44–$12.48 per share. Following these trades, she directly holds 27,585 shares, which include 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's stock purchase plan.

Orthofix Medical CFO Julie Andrews reported automatic share sales related to equity compensation. On March 4 and 5, 2026, she sold a total of 4,788 shares of Orthofix Medical common stock in open‑market transactions at weighted average prices of $12.9163 and $12.5508 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations in connection with the settlement of restricted stock units under a pre‑existing, mandated sell‑to‑cover arrangement approved by the Board’s Compensation and Talent Development Committee, and were executed without her discretion. After these transactions, she directly holds 88,746 shares, including 69,552 restricted stock units.

Orthofix Medical Inc. executive Lucas Vitale, listed as CP&BOO, reported selling a total of 2,312 shares of common stock in two open-market transactions on March 4 and March 5, 2026. The shares were sold at weighted average prices of $12.9163 and $12.5508 per share.

According to a footnote, these sales were made solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, committee-mandated sell-to-cover requirement, with no discretion exercised by Vitale. After these transactions, he held 164,718 shares and restricted stock units.

Orthofix Medical Inc. President & CEO Massimo Calafiore reported automatic sales of common stock tied to tax withholding on restricted stock units. On March 4, he sold 6,189 shares at a weighted average price of $12.9163, and on March 5, he sold 6,031 shares at a weighted average price of $12.5508, for a total of 12,220 shares.

The filing explains these shares were sold under a pre-existing sell-to-cover requirement to satisfy tax obligations when restricted stock units settled, and the sales were made without any exercise of discretion by him. After these transactions, he directly holds 320,136 shares of Orthofix common stock, including 221,042 restricted stock units.

Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported selling 1,536 shares of common stock in open-market transactions on March 4 and 5, 2026 at weighted average prices of $12.9163 and $12.5508 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations under a pre-existing sell-to-cover requirement approved by a board committee and were executed without his discretionary choice. After these transactions, he held 50,633 shares and restricted stock units in total, including 41,134 previously reported restricted stock units.

Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, reported selling a total of 2,559 shares of common stock in open-market transactions on March 4 and 5, 2026.

According to the disclosure, these sales were executed to satisfy tax withholding obligations related to the settlement of restricted stock units under a pre-approved, mandatory sell-to-cover program established by the Board’s Compensation and Talent Development Committee, and were carried out without any discretionary trading decision by the reporting person. After these transactions, McPherron directly owns 67,853 shares of Orthofix common stock, which includes 54,692 previously reported restricted stock units.

Orthofix Medical Inc. President, Global Spine, Max Reinhardt reported selling 2,133 shares of common stock in open-market transactions on March 4 and March 5, 2026. The shares were sold solely to satisfy tax withholding obligations from restricted stock unit settlement under a pre-approved sell-to-cover mandate, with no discretion exercised by him. After these sales, he directly held 25,348 shares, including 19,417 restricted stock units.

Orthofix Medical Inc. chief legal officer Jorge Andres Cedron reported automatic sales of common stock to cover tax withholding on recently settled restricted stock units. A total of 2,775 shares were sold in open‑market transactions on March 4–5 under a pre-existing, committee‑mandated sell-to-cover requirement.

The shares were sold at weighted-average prices of $12.9163 and $12.5508 per share across multiple trades within specified ranges, with no discretion exercised by Cedron. Following these transactions, he beneficially owns 62,749 shares of Orthofix common stock, including 53,902 previously reported restricted stock units.

Orthofix Medical Inc. President & CEO Massimo Calafiore received equity compensation awards on March 3, 2026. He was granted employee stock options for 273,279 shares at an exercise price of $0.00 and 115,119 shares of common stock in the form of restricted stock units.

The restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, Calafiore directly holds 332,356 shares of common stock, including previously reported restricted stock units, and 273,279 stock options.

Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, received equity awards on the form’s grant date. She was granted 54,656 stock options with an exercise right and 23,024 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.

The options and restricted stock units each vest in three equal one-third installments on the first, second, and third anniversaries of the grant date. After these awards, she directly holds 70,412 shares of common stock, which includes 37,557 previously reported restricted stock units and 1,066 shares acquired under Orthofix’s Stock Purchase Plan.

Orthofix Medical Inc. CFO Julie Andrews received new equity awards consisting of stock options and restricted stock units. On the grant date, she acquired employee stock options for 84,261 shares at an exercise price of $0.00 per share and 35,495 shares of common stock as a restricted stock unit award.

The footnotes state that the restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, her directly held common stock, including previously reported restricted stock units, totaled 93,534 shares.

Orthofix Medical Inc. reported that Chief Legal Officer Jorge Andres Cedron received equity awards in the form of stock options and restricted stock units. On March 3, 2026, he was granted 54,656 employee stock options and 23,024 shares of common stock as a grant/award acquisition.

The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date. The options also vest and become exercisable in equal one-third installments on each of the first three anniversaries. Following the stock grant, he directly holds 65,524 shares of common stock, which includes 36,767 previously reported restricted stock units.

Orthofix Medical Inc. reported that executive Lucas Vitale, its CP&BOO, acquired new equity awards. On March 3, 2026, he received 45,546 employee stock options and a separate grant of 19,186 shares of common stock in the form of restricted stock units.

The restricted stock units vest in three equal installments, with one-third of the shares vesting on each of the first, second, and third anniversaries of the grant date. Following these grants, Vitale directly holds 167,030 shares of common stock, including previously reported restricted stock units and shares acquired under Orthofix’s Stock Purchase Plan.

Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported equity awards on March 3, 2026. He received 50,101 employee stock options with an exercise right to buy Orthofix common shares and a grant of 21,105 shares of common stock as restricted stock units at no cash cost.

The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date, and the options vest on the same three-year schedule. Following these grants, Fisher directly owns 52,169 shares of common stock, which include previously reported restricted stock units and 948 shares acquired under Orthofix’s Stock Purchase Plan, and holds 50,101 stock options.

Orthofix Medical Inc. large shareholder entities associated with Engine Capital reported new open-market purchases of common stock. On February 24–25, 2026, Engine Capital, L.P. and Engine Lift Capital, LP bought a combined 137,858 shares at prices of $12.5455 and $12.9634 per share, all held indirectly. The filing also reports updated indirect holdings for Engine Jet Capital, L.P. Each of the listed Engine Capital entities and Arnaud Ajdler may be deemed part of a Section 13(d) group that collectively beneficially owns more than 10% of Orthofix’s common stock, while disclaiming beneficial ownership beyond their pecuniary interests.

Orthofix Medical Inc.'s CFO Julie Andrews reported a sale of 4,873 shares of common stock on January 16, 2026 at a price of $14.38 per share. This was a Form 4 insider transaction.

According to the footnotes, the shares were sold solely to cover tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, mandatory sell-to-cover arrangement approved by the board’s Compensation and Talent Development Committee. The sale was made without any exercise of discretion by the reporting person.

After this transaction, Andrews beneficially owned 58,039 shares of Orthofix common stock, which includes 45,590 previously reported restricted stock units.

Orthofix Medical Inc. President & CEO Massimo Calafiore reported automatic sales of company stock to cover taxes linked to vesting equity awards. On January 9, 2026, 9,600 shares of common stock were sold at a weighted average price of $15.8235, and on January 12, 2026, 9,797 shares were sold at a weighted average price of $15.2138. The filing explains these transactions were made under a pre-existing, mandated sell-to-cover arrangement approved by the board’s Compensation and Talent Development Committee, with no discretion exercised by the executive. After these sales, Calafiore beneficially owned 217,237 shares of Orthofix common stock, including previously reported deferred stock units and shares acquired under the company’s stock purchase plan.